Evrenzo self attestation

Are you a Healthcare Professional?

This site is intended only for Healthcare Professionals, particularly those who are experienced in the management of anaemia associated with chronic kidney disease.

I AM NOT A HEALTHCARE PROFESSIONAL
evrenzo leavingsoon

You are leaving the website

You are now leaving an Astellas Pharma Ltd. website.
Astellas bears no responsibility for the content of any 3rd party material
nor how it might be used. Click OK to proceed.

The patient perspective

  • The burden on patients

    Anaemia of CKD has a substantial impact on patients’ lives1

    It is associated with poor clinical outcomes and reduced quality of life.1,2

    Patient perspective1

    Common symptoms of CKD patients. Adapted from reference 1, figure made by Astellas.

    Symptoms of anaemia overlap with those of CKD1 and may add to the burden of CKD.2

    Untreated anaemia may accelerate progression of CKD.1,3

    Current management of CKD can be sub-optimal2,4

    Some patients with anaemia of CKD are not treated to target3-5

    Concern about the risks of over-correcting haemoglobin may lead to under-treatment of patients.4

    How does it feel to live with anaemia of CKD?

    Effective control of Hb?

    Image of smiling man painting chair

    Convenience?

    Image of smiling woman

    Tolerability?

    Image of man holding plant(close up)

    CKD, chronic kidney disease; GI, gastrointestinal; Hb, haemoglobin.

    References

    • Mathias SD, Blum SI, Sikirica V et al. Symptoms and impacts in anemia of chronic kidney disease. J Patient-Reported Outcomes. 2020;4,64. https://doi.org/10.1186/s41687-020-00215-8.
    • Guedes M, Robinson BM, Obrador G et al. Management of Anemia in Nondialysis Chronic Kidney Disease: Current Recommendations, Real-World Practice, and Patient Perspectives. Kidney360. 2020;1(8):855-62
    • Dowling TC. Prevalence, etiology, and consequences of anemia and clinical and economic benefits of anemia correction in patients with chronic kidney disease: an overview. Am J Health-System Pharmacy. 2007;64(13 suppl 8):S3–S7.
    • Lopes MB, Zee j, Guedes M. A real-world longitudinal study of anemia management in non-dialysis-dependent chronic kidney disease patients: a multinational analysis of CKDopps. Nature Scientific Reports. 2021;11:1784. https://doi.org/10.1038/s41598-020-79254-6.
    • Stauffer ME, Fan T. Prevalence of anemia in chronic kidney disease in the United States. PLoS ONE. 2014;9(1):e84943. doi:10.1371/journal.pone.0084943

  • Patient benefits of EVRENZO

    EVRENZO can help CKD patients achieve and maintain Hb targets2

    At home with their treatment.

    Oral treatment that can be taken at home1

    • no special storage instructions3

    • no need to administer in hospital1

    Image of guitar being played (close up)

    Three times weekly dosage1

    Image of woman watering plants (close up)

    Reduced use of IV iron compared with ESA2

    Image of smiling man painting chair

    CKD, chronic kidney disease; DD, dialysis-dependent; ESA, erythropoiesis-stimulating agent; IV, intravenous; NDD, non-dialysis-dependent; TIW, three times weekly.

    Reference

    • EVRENZO SmPC 09.2024 sect. 4.2
    • EVRENZO SmPC 09.2024 sect. 5.1
    • EVRENZO SmPC 09.2024 sect. 6.4

  • Which of your patients can benefit most?

    Non-dialysis patients

    Image of man holding plant (close up)

    Routine oral iron
    Iron replete
    Hb below target
    Poor adherence to oral iron

    Image of smiling woman

    Routine IV iron
    Iron replete
    Hb below target
    Difficulty attending
    clinic for IV iron


    EVRENZO is an oral tablet that provides Hb correction and maintenance superior to placebo (p<0.0001) and comparable to ESA (p=0.844), with reduced use of IV iron1

    Just started dialysis

    Image of smiling man painting chair

    Routine iron
    Iron replete
    Hb below target


    EVRENZO is an oral tablet that provides comparable Hb correction (95% CI; 0.28 [0.110, 0.451]) and maintenance (95% CI; 0.30 [0.228, 0.373]) to ESA, with reduced use of IV iron1


    How can your patients get more out of EVRENZO?

    The leaflets below provide educational materials and simple advice to support patients during their treatment journey.

    EVRENZO disease education booklet image

    Disease education booklet

    A general information for patients having anaemia of CKD, information about what is anaemia, symptoms, tests etc, and include a diary for the patients to make their notes for the next clinic visit

    DOWNLOAD

    DD, dialysis-dependent; ESA, erythropoiesis-stimulating agent; Hb, haemoglobin; IV, intravenous.

    Reference

    • EVRENZO SmPC 09.2024 sect. 5.1